<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=580450&amp;fmt=gif">

UCB: an appetite for disruption

Posted by Neoteryx on Oct 2, 2017 2:26:00 AM
Neoteryx

In a column for Bioanalysis Zone, Stuart Kushon, the head of research and development at Neoteryx, takes a look at what traits are present in companies who implement microsampling and other disruptive technologies successfully. He offered three examples of companies that have what it takes to do disruption well. Today, we'll look at a fourth.

The global pharmaceutical company UCB has always been on the lookout for better ways of doing things. The team at UCB understand the hurdles of deployment for blood microsampling, and they can see this novel technology as part of a larger, better plan for conducting clinical trials.

a wide angle shot of the UCB corporate head quartersMicrosampling is more convenient for the patient and allows patients and clinical staff to collect reliable sample volumes with minimal training – its implications span the spectrum of the clinical trials process. Now that UCB has implemented microsampling, it has the option to obtain more data for better insights into drug metabolism. UCB saw the potential in this technology to facilitate patient recruitment from a larger pool of participants, particularly pediatrics, and was willing to embrace the required commitment and change.

The implementation of microsampling is an ongoing strategy for UCB. This requires bridging studies to ensure data from microsamples matches results from standard blood collection.  Using this process, UCB have gained confidence in employing microsampling as a key part of its toolbox for their current and future clinical trials.

Furthermore, shipping dried microsamples from clinical trial centers is easier, safer, and significantly less expensive than shipping blood tubes on ice.  Simply put, microsampling simplifies the logistics of sample handling.

Change in any workflow introduces challenges. Implementation of UCB’s microsampling strategy required some inconvenience and, more importantly, vision. Nevertheless, UCB’s thoughtful and deliberate strategy of initial consultation, evaluation and measured implementation, of microsampling is now on track to allow its team and its patients to reap the benefits of this novel technology.

Want to learn more, in depth? On Thursday, October 5th, John Smeraglia and David Sciberras of UCB will participate in a live webiar, How to Successfully Implement Microsampling (and Other Disruptive Technologies), presented by Neoteryx and Bioanalysis Zone. Click here check your time zone and to register now.

Topics: Clinical Trials